{"id":33002,"date":"2024-07-03T12:45:29","date_gmt":"2024-07-03T12:45:29","guid":{"rendered":"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/"},"modified":"2024-07-03T12:45:29","modified_gmt":"2024-07-03T12:45:29","slug":"estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e","status":"publish","type":"post","link":"https:\/\/ibima.eu\/en\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/","title":{"rendered":"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN)"},"content":{"rendered":"<p>MANUEL COBO DOLS &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>","protected":false},"excerpt":{"rendered":"<p>MANUEL COBO DOLS &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2296],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.0 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN) - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN) - Ibima\" \/>\n<meta property=\"og:description\" content=\"MANUEL COBO DOLS &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-03T12:45:29+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/\",\"url\":\"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/\",\"name\":\"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN) - Ibima\",\"isPartOf\":{\"@id\":\"https:\/\/ibima.eu\/es\/#website\"},\"datePublished\":\"2024-07-03T12:45:29+00:00\",\"dateModified\":\"2024-07-03T12:45:29+00:00\",\"author\":{\"@id\":\"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/ibima.eu\/es\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ibima.eu\/es\/#website\",\"url\":\"https:\/\/ibima.eu\/es\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ibima.eu\/es\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ibima.eu\/es\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1438f1fd1109c815d89b9163757252a6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1438f1fd1109c815d89b9163757252a6?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\/\/ibima.eu\"],\"url\":\"https:\/\/ibima.eu\/en\/author\/prodriguez\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN) - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/","og_locale":"en_GB","og_type":"article","og_title":"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN) - Ibima","og_description":"MANUEL COBO DOLS &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.","og_url":"https:\/\/ibima.eu\/en\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/","og_site_name":"Ibima","article_published_time":"2024-07-03T12:45:29+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/","url":"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/","name":"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN) - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2024-07-03T12:45:29+00:00","dateModified":"2024-07-03T12:45:29+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-prospectivo-no-intervencionista-multicentrico-para-determinar-la-prevalencia-de-mutaciones-del-gen-egfr-en-pacientes-con-cancer-de-pulmon-de-celula-no-pequena-resecable-en-estadio-temprano-e\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio prospectivo, no intervencionista, multic\u00e9ntrico para determinar la prevalencia de mutaciones del gen EGFR en pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lula no peque\u00f1a resecable en estad\u00edo temprano en Espa\u00f1a. Prevalencia de mEGFR en pacientes con CPCNP resecable en estad\u00edo temprano en Espa\u00f1a (ORIGEN)"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1438f1fd1109c815d89b9163757252a6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1438f1fd1109c815d89b9163757252a6?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/en\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/33002"}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=33002"}],"version-history":[{"count":2,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/33002\/revisions"}],"predecessor-version":[{"id":41867,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/posts\/33002\/revisions\/41867"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=33002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/categories?post=33002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/tags?post=33002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}